Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.

Fumihiko Sakai Norihiro Suzuki Byung-Kun KimYoshihisa TatsuokaNoboru ImaiXiaoping NingMiki IshidaKaori NaganoKatsuhiro IbaHiroyuki KondoNobuyuki Koga

Published in: Headache (2021)

Fremanezumab prevents episodic migraine in Japanese and Korean patients to a similar extent than in previously reported populations with no new safety concerns.

Keyphrases

double blind
placebo controlled
end stage renal disease
phase iii
clinical trial
ejection fraction
newly diagnosed
phase ii
study protocol
chronic kidney disease
peritoneal dialysis
prognostic factors
randomized controlled trial
open label
cross sectional
radiation therapy
phase ii study